Lee Y, Jeong M, Park J, Jung H, Lee H
Exp Mol Med. 2023; 55(10):2085-2096.
PMID: 37779140
PMC: 10618257.
DOI: 10.1038/s12276-023-01086-x.
Cachumba J, Antunes F, Peres G, Brumano L, Santos J, da Silva S
Braz J Microbiol. 2016; 47 Suppl 1:77-85.
PMID: 27866936
PMC: 5156506.
DOI: 10.1016/j.bjm.2016.10.004.
Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K
AAPS J. 2016; 18(2):311-20.
PMID: 26821802
PMC: 4779092.
DOI: 10.1208/s12248-016-9878-1.
Ozel T, White S, Nguyen E, Moy A, Brenes N, Choi B
Lasers Surg Med. 2015; 47(7):579-594.
PMID: 26189505
PMC: 4716005.
DOI: 10.1002/lsm.22396.
Siddalingappa B, Benson H, Brown D, Batty K, Chen Y
PLoS One. 2015; 10(3):e0118824.
PMID: 25799413
PMC: 4370505.
DOI: 10.1371/journal.pone.0118824.
Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I
J Thromb Haemost. 2014; 12(2):220-8.
PMID: 24641308
PMC: 4166693.
DOI: 10.1111/jth.12477.
PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins.
Schlapschy M, Binder U, Borger C, Theobald I, Wachinger K, Kisling S
Protein Eng Des Sel. 2013; 26(8):489-501.
PMID: 23754528
PMC: 3715784.
DOI: 10.1093/protein/gzt023.
Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.
Mikhail A
J Blood Med. 2012; 3:25-31.
PMID: 22719216
PMC: 3377433.
DOI: 10.2147/JBM.S23270.
Solubilization of native integral membrane proteins in aqueous buffer by noncovalent chelation with monomethoxy poly(ethylene glycol) (mPEG) polymers.
Janaratne T, Okach L, Brock A, Lesley S
Bioconjug Chem. 2011; 22(8):1513-8.
PMID: 21740061
PMC: 3160772.
DOI: 10.1021/bc200019x.
A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats.
He X, Yin H, Wu J, Zhang K, Liu Y, Yuan T
J Zhejiang Univ Sci B. 2011; 12(1):32-9.
PMID: 21194184
PMC: 3017414.
DOI: 10.1631/jzus.B1000085.
Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin.
Zhang R, Jain S, Rowland M, Hussain N, Agarwal M, Gregoriadis G
J Diabetes Sci Technol. 2010; 4(3):532-9.
PMID: 20513317
PMC: 2901028.
DOI: 10.1177/193229681000400305.
Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.
Barnes T, Moots R
Int J Nanomedicine. 2007; 2(1):3-7.
PMID: 17722505
PMC: 2673817.
DOI: 10.2147/nano.2007.2.1.3.
Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.
Parveen S, Sahoo S
Clin Pharmacokinet. 2006; 45(10):965-88.
PMID: 16984211
DOI: 10.2165/00003088-200645100-00002.
Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L, Savaraj N
Expert Opin Investig Drugs. 2006; 15(7):815-22.
PMID: 16787144
PMC: 3086545.
DOI: 10.1517/13543784.15.7.815.
Characterizing the modification of surface proteins with poly(ethylene glycol) to interrupt platelet adhesion.
Xu H, Kaar J, Russell A, Wagner W
Biomaterials. 2006; 27(16):3125-35.
PMID: 16457880
PMC: 2857701.
DOI: 10.1016/j.biomaterials.2006.01.012.
Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
Mager D, Neuteboom B, Jusko W
Pharm Res. 2005; 22(1):58-61.
PMID: 15771230
DOI: 10.1007/s11095-004-9009-z.
Topical superoxide dismutase reduces post-irradiation breast cancer fibrosis.
Campana F, Zervoudis S, Perdereau B, Gez E, Fourquet A, Badiu C
J Cell Mol Med. 2004; 8(1):109-16.
PMID: 15090266
PMC: 6740277.
DOI: 10.1111/j.1582-4934.2004.tb00265.x.
